secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001140361-25-041563
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech launches up to $11.1M registered direct offering; Sep 30 cash $26.2M
--------------------------------------------------------------------------------

- Offering of 5.8M shares (or pre-funded warrants) at $0.91 with warrants exercisable at $1.00 per share.
- Initial gross proceeds ~$5.3M; up to additional $5.8M if warrants fully exercised.
- Proceeds for VERSATILE-003 Phase 3 trial and FDA discussions for accelerated PDS0101 pathway.
- Existing warrants amended: exercise price reduced from $1.50 to $1.00, exercisable six months after close.
- 60-day lock-up agreements for directors and officers; Craig-Hallum as placement agent at 6.0% fee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041563/0001140361-25-041563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125041563/ny20058850x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer